UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Infinity Pharmaceuticals on 4Q Results

In a report published Wednesday, J.P. Morgan reiterated its Overweight rating on Infinity Pharmaceuticals (NASDAQ: INFI ), and raised its price target from $42.00 to $53.00. J.P. Morgan noted, “INFI reported 4Q results and while the financials were uneventful, there was an encouraging incremental clinical update regarding IPI-145 (for hematologic